Hypersomnia Foundation

Archive for 'News'

Sleep Disorders and Social Security– What You Need to Know

Social Security Disability Series: Part 2

Sleep Disorders and Social Security Disability – What You Need to Know

By Anjel Burgess, JD

Jennie has been fortunate enough to secure her short-term disability benefits. She has also hired an Attorney to assist her with the Social Security Disability application process. Although her family encouraged her to “file on her own instead of paying out of pocket to hire an attorney,” Jennie has learned throughSomnusNooze that Social Security Disability attorneys are not paid by a retainer, as many attorneys are. Rather, they work on a contingency basis, which means that Jennie does not have to pay out of pocket to get representation. For the attorney to get paid, two conditions must be met:

  1. The attorney must win Jennie’s case.
  2. Jennie must be entitled to past-due benefits (also known as back pay).

If both conditions are met, the Social Security Administration (SSA) will pay Jennie’s attorney 25% of Jennie’s back pay, up to a maximum of $6,000. Since obtaining the benefits is of the utmost importance to Jennie, she has decided that she can’t afford NOT to have an attorney. She has hired an attorney who will file an initial application for her and represent her through each step of the process.

Jennie’s attorney has explained to her that most people who receive Social Security Disability benefits have been through a three-step process and that it may take two years or more before she is approved (note that in some states, it is a 2-step process, as the Reconsideration step is eliminated). These steps include the following.

  1. Initial – Roughly 30% to 35% of applicants are approved at this level. Once SSA receives the initial application, they request medical records from Jennie’s providers. Once the SSA receives Jennie’s medical records, SSA will have its own physician or psychologist (or both a physician and psychologist) review the medical records to give their opinion as to what limitations they believe that Jennie has, as well as the impact of those limitations on her ability to work. This would also include a review of the opinion of Dr. Wonderful and any other of Jennie’s treating physicians. Oftentimes, SSA will decide that they need an outside opinion in making their decision. If this occurs, the SSA may require that Jennie be examined by an independent physician or psychologist (at SSA’s expense) who may not have an expertise in idiopathic hypersomnia. This independent professional then prepares a report that summarizes her or his observations and professional opinion. If the case is denied initially, Jennie can appeal.
  2.  Reconsideration – Roughly 7% to 10% of applicants are approved at this level. At the Reconsideration step, SSA obtains updated medical records and completes another internal review of Jennie’s file to see if any new evidence would result in a favorable outcome. It is possible that the SSA may send Jennie out for an independent examination at this stage as well. Again, if Jennie is denied, she can appeal.
  3. Hearing – Roughly 50% to 55% of the remaining applicants are approved at this level. This is the stage at which most people are awarded benefits, particularly after attending a hearing in front of an administrative law judge. The hearing is the opportunity for Jennie and her attorney to present the big picture to a judge. The big picture includes all medical records and testimony from Jennie herself. Jennie’s attorney will also have the opportunity to make oral and written arguments on Jennie’s behalf.

The common theme in each step of the process is medical records. Medical records are vital in a disability case because they can provide objective support for an individual’s complaints. For Jennie, her medical records tell the story of a very symptomatic individual who tried multiple medications but could only be productive for about 3 hours throughout the day. Her doctor ruled out many other conditions, and was able to confirm the diagnosis of idiopathic hypersomnia via a polysomnogram and Multiple Sleep Latency Test. Jennie’s medical records provide proof that she has idiopathic hypersomnia and authenticate her symptoms, which are reasonably due to idiopathic hypersomnia.

If you, too, are ready to file for Social Security Disability or have been denied at any step in the process, contact a qualified Social Security Disability Attorney to assist you with the process.

Anjel Burgess is a partner/attorney at the Law Firm of Burgess and Christensen located in Marietta, GA. She exclusively practices Social Security Disability Law for adults and children, as well as the ancillary areas of Guardianships and Special Needs Trusts. By doing so, she has been able to make a positive difference in the daily lives of people who need help the most. You may reach her at Anjel@DisabilityHelpLine.com or 770-422-8111. You can learn more about her services at www.DisabilityHelpLine.com

Have you joined the registry yet?
A patient registry is a collection that is established to collect standardized information about a group of patients who share a common condition or experience. In the case of the Hypersomnia Foundation Registry at CoRDS  (Coordination of Rare Diseases at Sanford), the people who participate have one of the central disorders of hypersomnolence: idiopathic hypersomnia, Kleine-Levin syndrome, or narcolepsy (type 1 or 2). Becoming part of the registry is easy and it could help solve the puzzle of hypersomnia! Simply go to http://www.sanfordresearch.org/cords/ and click on the ENROLL NOW button.

A patient registry is a collection that is established to collect standardized information about a group of patients who share a common condition or experience. In the case of the Hypersomnia Foundation Registry at CoRDS (Coordination of Rare Diseases at Sanford), the people who participate have one of the central disorders of hypersomnolence: idiopathic hypersomnia, Kleine-Levin syndrome, or narcolepsy (type 1 or 2). Becoming part of the registry is easy and it could help solve the puzzle of hypersomnia! Simply go to http://www.sanfordresearch.org/cords/ and click on the ENROLL NOW button.

 

Watch Beyond Sleepy in the Mile-High City

Denver6

Were you one of the more than 1250 people who joined us at Beyond Sleepy in the Mile-High City, the Hypersomnia Foundation’s Regional Conference, in person and online on June 12, 2016? If not, you can still watch the conference in its entirety by registering at http://www.hypersomniafoundation.org/2016-hypersomnia-regional-conference-register/. If you previously registered and missed any part of the program–or simply want to watch it again–please go to http://www.hypersomniafoundation.org/2016-hypersomnia-regional-conference-live/. The video will only be up for two more weeks!

 

Posted in: Action, Awareness, BeyondSleepy, Conference, CoRDS Registry, Education, Hypersomnia, idiopathic hypersomna, Kleine-Levin syndrome, narcolepsy, News, SomnusNooze, SSDI

Leave a Comment (0) →

NEWSFLASH!

With seating beyond planned capacity at the conference in Denver and to make the #BeyondSleepy conference more accessible, we will be streaming the entirety of the conference, including the question-and-answer portion. Thanks to a tech-savvy volunteer,Strike we will not only be livetweeting the conference from our Twitter account (@HypersomniaNews), but will also be able to accept your relevant questions. So tweet your questions using the hashtag #AskBeyondSleepy.

Please don’t wait until the last minute to register! Our website is a bit crotchety and slow, so if everyone tries registers at once immediately before the conference, you may miss part of the program!

We look forward to your participation in the conference!

Posted in: BeyondSleepy, Conference, Hypersomnia, idiopathic hypersomna, Kleine-Levin syndrome, narcolepsy, News, Social Media, SomnusNooze

Leave a Comment (0) →

Act Today and Let Your Voice Be Heard

Very recently, the Hypersomnia Foundation became aware of an opportunity to help shape the future of sleep research. The National Institutes of Health, the primary source of funding for medical research in the United States, has issued a Request for Information, which you can view at: https://grants.nih.gov/grants/guide/notice-files/NOT-HL-16-312.html.

The final date to submit your comments has been extended to today, May 16, 2016.Screen Shot 2016-05-16 at 12.41.44 PM

Last week, we sent an email to everyone in our database to encourage you to make your voices heard. We are urging you again to act today. Please share your hypersomnia story with the people who determine medical research priorities and allocate funds.

  • Tell them why the currently available diagnostic tools and lack of awareness about hypersomnia led to a lengthy delay in your diagnosis.
  • Tell them why research into the cause of and effective treatments for hypersomnia are so desperately needed.
  • Tell them why we need a cure as soon as possible because hypersomnia is limiting your ability to achieve your dreams, complete your education, or even provide financially for your family.

Please join your voice with ours as we fight to secure the place of hypersomnia at the top of the nation’s sleep research agenda. The Hypersomnia Foundation Board of Directors has submitted the following response, and we encourage you to send your comments and suggestions to the NIH, as you deem appropriate, at rfi-sleepplan2016@collaboration.nhlbi.nih.gov.


 

Hypersomnia Foundation Response
to the National Institutes of Health’s Request for Information:

For nearly a century, the study of sleep and its function(s) in health and disease has been principally focused within approaches that center on not enough sleep. Although excessive daytime sleepiness (EDS), cognitive dissonance, and other symptoms not surprisingly result from sleep deprivation, central disorders of hypersomnolence (CDH; e.g., idiopathic hypersomnia, Kleine-Levin syndrome,
narcolepsy type 1 [NT1], and narcolepsy type 2 [NT2]) in humans (in which EDS is often accompanied by extremes of sleep length) emerge spontaneously. Studying patients with CDH has already proven to be fertile ground for investigation, as evidenced by the discovery that loss of brain hypocretin causes narcolepsy with
cataplexy (i.e., NT1). Yet, for the other CDH, there remains a large unmet clinical need, with further research and development prime for discovery and the potential for extraordinary translational opportunities.

Symptoms of CDH can be disabling, and because, for example in NT1, they also begin in adolescence or young adulthood, are chronic, sometimes progressive, go undiagnosed or misdiagnosed for decades, and respond variably to medications.
Despite advances around NT1, the knowledge gained has not translated smoothly to
the clinical realm. Diagnoses of CDH inclusive of NT1 since 1975 have relied upon a
forty-year-old test (viz., the Multiple Sleep Latency Test [MSLT]) that is cost, time,
and labor intensive and that was born of practical necessity and subsequently
tweaked to specifically identify NT1. In 2006, two preeminent sleep researchers concluded that the MSLT yields “a large number of false-positives” and that an increased daytime propensity to REM-sleep—traditionally accepted to be the sole domain of NT1—does “not appear to have any specific pathognomonic significance.” Yet, in 2016, the MSLT remains the gold standard that drives diagnoses and all that it implies. For clinician scientists, this means, for example, how clinical trials are designed and studies of heritability are conducted. Even more so, for patients, this has enormous implications for prognosis, treatment choice, access to medication(s), and accommodations/disability status.

There are currently no FDA-approved treatments for the CDH—medication choice being limited to those for narcolepsy. Since the 1930s, conventional
psychostimulants such as ephedrine have been used to treat NT1. The majority of the current pharmacological armamentarium and drug development are similarly designed and focused upon promoting wakefulness by enhancing brain monoamines. Drugs more directly designed to replace hypocretin continue in development 16 years after the discovery of hypocretin. An alternative construct in approaching the biology and treatment of CDH has recently been proposed that appears to hold great promise for many patients. People with CDH without NT1 (i.e., hypocretin being intact) do not appear to suffer from any “loss of function” per se but, rather, a gain of function in sleep-promoting brain circuits. Thus, pharmacologic agents that antagonize the sleep-promoting and consciousness-dampening neurotransmitter gammaaminobutyric acid (GABA), such as flumazenil, clarithromycin, and pentylenetetrazol, have either been demonstrated to be effective or are in clinical trials for CDH patients in whom traditional wake-promoting agents have not been helpful.

We advocate for initiatives to fund discovery research that translates to improve the human condition of people with CDH in whom sleep is prolonged and ostensibly persists into “wake.” Enhanced recognition and improved treatments call for greater understanding of not only the clinical spectrum of CDH and the natural history of these disorders, but also mechanistic understanding of their biological underpinnings. Diagnostic tools that are highly discriminative and designed to capture more than just EDS and an increased daytime propensity to REM sleep are an absolute necessity. CDH remain diagnoses of exclusion such that greater understanding of potential mimics—which themselves would enhance mechanistic understanding of sleep—and biomarker discovery are also high priorities. As there are numerous stakeholders in such endeavors, as evidenced in the summary provided above, the absolute need to encourage greater dialogue and collaboration among patients, patient advocacy groups, professional organizations representing sleep physicians, funding agencies, and industry cannot be understated. With increasing dissemination of knowledge through many means, not the least of which includes social media, patient consumers with CDH-like symptoms have become increasingly knowledgeable. They are acutely aware that CDH outside the realm of NT1 is not well served by current medical knowledge or practice in this realm. Accepting the status quo risks alienating the public and medical consumer.

We would, therefore, propose including a sleep neurobiologist on the NHLBI Sleep
Disorders Research Advisory Board and developing mechanisms for solicitation of
program projects and set-aside funds specifically to research hypersomnia, with requests for proposals to prioritize filling unmet clinical needs in the following areas:

R37 Javits Neuroscience Investigator Award
NIH EUREKA grants
R13 funding to support conferences
T32 grants for postdoctoral study
RFAs and more specifically RFPs
SBRI funding for better diagnostic tools

Because the breadth of scientific inquiry or line of investigation needs incredible resources and sustainability, we would advocate for funding initiatives with set-aside monies at all levels of training, including predoctoral, doctoral, postdoctoral, junior investigator, and senior investigators, and we envision promoting set-aside monies for all the Career Development K Awards for investigators with projects relevant to CDH.


 

SN-Image

Learn about the latest hypersomnia research on June 12th at the Hypersomnia Foundation’s regional conference, Beyond Sleepy in the Mile High City. Scientists will share findings from their recently completed clinical trials and other ongoing studies, lead us on a journey through the drug discovery and approval process, and help us to cope with the daily struggles of hypersomnia. You will also learn how your future participation in the registry can help to solve the puzzle of hypersomnia.

Tickets are running out so order your $25 ticket online to join us in person in Denver or wait until June 1 to sign up for a live Internet stream of the conference, brought to you free of charge through the generous support of Balance Therapeutics, Inc., and Flamel Technologies, SA.

 

 

 

Posted in: Action, Awareness, Education, Hypersomnia, idiopathic hypersomna, Kleine-Levin syndrome, narcolepsy, News, Research, SomnusNooze

Leave a Comment (0) →

Calcium-dependent Pathway Helps to Regulate Sleep Duration

Background

How do our brains control when we go to sleep and when we wake up? Previous studies have tried to answer this question, but, despite years of research, our understanding of this process is incomplete. Therefore, the goal of this study was to identify the elusive mechanisms underlying the control of sleep.

Who were the researchers and what did they do?

Dr. Ueda and colleagues at the University of Tokyo constructed a computer model (called computational modeling) of a neuron (a type of cell in the brain) during sleep to predict what pathway(s) might be responsible for sleep regulation. They then manipulated the proposed pathway in mice to test if the computer model was correct. Dr. Ueda and colleagues employed cutting-edge techniques to either remove the proposed pathway gene products from mice using genetic engineering (called knockout mice), or block the proposed pathway gene products using drugs (called pharmacologic inhibition). The authors then measured how these experimental manipulations of the proposed pathway in mice impacted sleep.

What were the results of the study?

This study revealed that the proposed pathway from the computational model does indeed control sleep duration in mice. Seven genes involved in the pathway emerged as having effects on sleep duration, out of a total 21 examined. The identified genes are involved in the regulation of a calcium-dependent pathway in neurons. Interestingly, changes in this calcium-dependent pathway can increase or decrease sleep duration.

What are the authors’ conclusions?

The authors conclude that this calcium-dependent pathway helps to regulate sleep duration. Future research in this pathway may help uncover the “missing switch between sleep/wake cycles.” This crucial research will lead to a better understanding of normal sleep function, in addition to associated sleep and psychiatric disorders. 

 

Tatsuki F, Sunagawa GA, Shi S, et al. Involvement of Ca(2+)-dependent hyperpolarization in sleep duration in mammals. Neuron. 2016;90(1):70-85.

A video overview of this research is available from the authors at https://www.youtube.com/watch?v=W4NrSa1R4mU

 

 

Conference rectangle Image
Learn about the latest hypersomnia research on June 12th at the Hypersomnia Foundation’s regional conference, Beyond Sleepy in the Mile High City. Scientists will share findings from their recently completed clinical trials and other ongoing studies, lead us on a journey through the drug discovery and approval process, and help us to cope with the daily struggles of hypersomnia. You will also learn how your future participation in the registry can help to solve the puzzle of hypersomnia.

Order your $25 ticket on line to join us in person in Denver or wait until June 1 to sign up for a live Internet stream of the conference, brought to you free of charge through the generous support of Balance Therapeutics, Inc., and Flamel Technologies, SA.

Posted in: Conference, News, Research, SomnusNooze

Leave a Comment (0) →

Thank you – We Couldn’t Have Done It Without You!

thank you

“Overwhelmed!” “Excited!” “Incredibly grateful!”at the Hypersomnia Foundation, we are thrilled beyond belief  following our “Giving Tuesday” campaign that expanded beyond a single day and actually ran through the end of 2015. Your incredible generosity not only met, but far exceeded, the Board members’ challenge to match their pledges.

Inspired by your support and encouragement, we will make 2016, our third year, the Hypersomnia Foundation’s most effective and successful year. But, before we look forward, let’s take a moment to reflect on what you—the Hypersomnia Foundation’s donors, volunteers and supporters—made possible in 2015.

  • The National Institute of Neurological Disorders and Stroke at the National Institutes of Health includes the Hypersomnia Foundation as a source of information on hypersomnia; http://www.ninds.nih.gov/disorders/hypersomnia/hypersomnia.htm.
  • The Board of Directors has expanded to seven members, who bring diverse knowledge and perspectives toward achieving the Foundation’s mission.
  • The Medical Advisory Board, now comprising six world-renowned clinicians, reviews and approves all medical information that the Hypersomnia Foundation publishes.
  • Awareness is growing: more than 1000 people now receive the SomnusNooze newsletter at least once a week, and physicians’ offices have distributed more than 2,000 brochures.
  • The web-based Physician Directory launched in July and now provides contact information for more than 40 physicians.
  • The successful 2015 Hypersomnia Conference provided education and support for the 240 attendees, including people with hypersomnia, healthcare professionals, researchers, and supporters from 28 states and 5 countries. Dr. Isabelle Arnulf’s keynote presentation led the way to break-out sessions, physician roundtable discussions, and research updates.
  • SnoozeTV – created in 2015, and presented as a live-interactive broadcast through Google Hangout, will be undergoing a facelift in 2016, with a new format, as will other Hypersomnia Foundation social media platforms.

Every dollar given to the Hypersomnia Foundation ensures that this work continues and even expands. As an all-volunteer organization, the Hypersomnia Foundation has big plans for 2016, including increasing volunteer input, improving our means to keep you informed of the latest hypersomnia-related news, developing the Scientific and Corporate Advisory Boards, and building a research grants program.

With sincere thanks and gratitude,

The entire Board of the Hypersomnia Foundation

Posted in: News

Leave a Comment (0) →

The Hypersomnia Foundation Welcomes New Board Members

We are pleased to announce that Scot Hulshizer, Celia King, and Diane Powell have recently been elected to the Board of Directors of the Hypersomnia Foundation. In addition to bringing unique strengths as the organization thrives and grows in both scope and depth, each new Board member has a loved one with hypersomnia. Over the coming months, we will be introducing you to Scot, Celia, and Diane. The Board is grateful to Jennifer Beard for her service in helping to launch the organization and is truly appreciative of her dedication and hard work on behalf of people everywhere with hypersomnia. The entire Board of Directors wishes Jennifer well in her future endeavors.

scot hulshizerScot Hulshizer joined the Hypersomnia Foundation’s Board of Directors as the Chief Financial Officer on August 19, 2015. Scot has held leadership roles at large companies as well as having been an investor and executive in several small businesses and entrepreneurial endeavors across the real estate, automotive, technology, and hospitality industries. He currently serves as the Director of Corporate Development for ADT at their corporate headquarters in Boca Raton, Florida. In addition to his professional endeavors, Scot serves as the Chair of the Scholarship Selection Committee for the Palm Beach chapter of Mensa and was formerly Chair of the Family Selection Committee for Habitat for Humanity in Texas. He earned his MBA from Kennesaw State University in 2007 while serving as Director of National Sales Operations for AT&T.

Scot first learned of hypersomnia as his wife, Danielle, struggled with a sleep disorder that disrupted her personal and professional life despite the best efforts of multiple neurologists and sleep specialists. She was one of the first patients to be diagnosed with this poorly understood condition by Dr. David Rye at Emory. Scot and Danielle have since provided support and encouragement for other individuals and families impacted by hypersomnia and were featured on the CNN show Vital Signs in 2015. By the way, in case you missed this show, you can watch it now. Just follow the link on our website at http://www.cnn.com/videos/intl_tv-shows/2015/04/15/spc-vital-signs-sleep-disorders-b.cnn.

Posted in: News

Leave a Comment (0) →

Wellsprings of Hope

…. if one advances confidently in the direction of his dreams, and endeavors to live the life which he has imagined, he will meet with a success unexpected in common hours.
Henry David Thoreau, Walden: Or, Life in the Woods

Just shy of a month ago, our mission’s cornerstones of education, advocacy and research were further realized in significant ways by the inspiring 2015 Hypersomnia Foundation Conference—which highlighted and created wellsprings of hope as we move into the future.

From our fortuitous origins 18 months ago that were indeed serendipitous, a seed was planted with the quip that “a foundation is needed” after a microburst of publicity about a hypersomnia patient at Emory. Thank you, Dr. Rye! Our three Founders—Cat Page-Rye, Jennifer Beard, and Catherine Friederich Murray—became the inaugural Board of Directors and nurtured that seed. Within months, the Foundation was shaping itself into a public nonprofit 501(c)(3) organization. Its groundwork was then laid, beginning with technology and social media, a Medical Advisory Board and a Scientific Advisory Board Chairperson, two additions to the Board of Directors, and connections reaching deeply into the hypersomnia community through our SomnusNooze e-newsletter, SnoozeTV, and Foundation literature (Hypersomnia Foundation Brochure, Clinical Trial Brochure, Tips for Supporters, and 10 (Free) Ways to Support the Hypersomnia Foundation). Initiatives took hold…volunteer recruitment (Share Your Journey entries, scientific writers, conference & events, and representatives attending other patient advocacy meetings and medical meetings), state registrations for fundraising, our Healthcare Provider Directory, the Flumazenil Shortage Impact Survey, the soon-to-be-launched Hypersomnia Foundation Patient Registry at Coordination of Rare Diseases at Sanford, and year-long preparation for the 2015 Hypersomnia Foundation Conference by conference co-chairs Diana Kimmel and Jennifer Beard. Each piece of the groundwork and each initiative has become a wellspring of hope in and of itself.

When the 250+ people gathered at Emory Conference Center last month, it became widely apparent that additional wellsprings were being created…our Conference Volunteer Team lead by Briana Espana; our keynote speakers and presenters; our sponsors, donors, and scholarship angels; and the many members of our community who expressed a desire to be involved with the work of the Foundation. Their anticipated generosity is much appreciated…in donating their time, talents, professional skills, and personal and business resources to affect the future—both their own and that of their loved ones.

Community matters. Involvement matters.
Where is YOUR place in the Foundation’s community?

Thoreau reminds us in Walden that Things do not change; we change. Consider ways in which you can be part of this community and let us know by sending a message to volunteer@hypersomniafoundation.org. Your involvement can make a difference.

Take the Flumazenil Shortage Impact Survey!

The Hypersomnia Foundation is documenting the effects of this medication shortage on the hypersomnia community. If you have been prescribed flumazenil, please respond to the survey. Your responses will be anonymously tallied and used to inform the public and those in the medical and pharmaceutical industries of the effects of such a shortage on the lives of those diagnosed with hypersomnia.
https://www.surveymonkey.com/s/Flumazenil_shortage

Take the Survey Here
We Want Your Feedback!

If you attended the 2015 Hypersomnia Foundation Conference, please complete this survey to give us feedback on how we did.
https://www.surveymonkey.com/s/HFConference2015

If you did not attend the 2015 Hypersomnia Foundation Conference, we want to know why. Please complete this survey to let us know.
https://www.surveymonkey.com/s/GXKZ5P5

Posted in: Conference, News, Uncategorized

Leave a Comment (0) →

Hypersomnia on CNN

Set your DVRs, check it out live, or catch a sneak peak, but don’t miss this program on sleep and idiopathic hypersomnia on CNN! Dr. Sanjay Gupta not only undergoes a Multiple Sleep Latency Test at Emory Sleep Lab, but also discusses idiopathic hypersomnia and its treatment with Dr. David Rye and Danielle Hulshizer. This episode of Vital Signs will air live on Saturday, April 25, 2015, at 3:30 PM EDT and again on Saturday, May 9, 2015, at 3:30 pm, EDT on CNN. In the meantime, you can watch the segments online by clicking on the following links.

PART 1: How important is a good night’s sleep?

PART 2: Tired all the time?

Posted in: Awareness, News, Press Coverage

Leave a Comment (0) →

Announcing a Conference Scholarship!

The Board of Directors of the Hypersomnia Foundation is pleased to announce the First Hypersomnia Foundation Conference Scholarship. This scholarship will cover the conference registration for one person to the Building Our Future Together conference to be held at the Emory Conference Center on July 18, 2015. Selection of the recipient will be by lottery.

If tight finances are keeping you from attending this year’s Hypersomnia Foundation Conference, please send a message to info@hypersomniafoundation.org with the subject line “Conference Scholarship.” Please include your name and email address. The deadline to submit requests for this scholarship is April 25, 2015. The winner will be announced on April 28, 2015.

Posted in: News

Leave a Comment (0) →

New Investigational Drug for Idiopathic Hypersomnia

This trial has completed recruiting participants.

First Industry-Sponsored Clinical Trial of a Treatment for Idiopathic Hypersomnia and Narcolepsy Without Cataplexy

 

new-investigational-drug-for-idiopathic-hypersomnia

NeuroTrials, Inc., has begun recruiting people to take part in the testing of a new treatment for idiopathic hypersomnia and narcolepsy without cataplexy. This small phase 1 study will test the safety and efficacy of a drug that is taken by mouth and swallowed. The study will also determine effective doses of the medication to treat these conditions. The researchers are looking for people who

  • Are 18-65 years old
  • Are in general good health with no other sleep disorders 

All study-related care and study drug will be provided at no cost. Qualified people may receive compensation. If you are interested in finding out more about this study, please visit the NeuroTrials website http://neurotrials.weebly.com/idiopathic-hypersomnia or https://www.facebook.com/arisestudy

Posted in: News, Research

Leave a Comment (0) →
Page 1 of 2 12